The SARS-CoV T-cell peptide antigens set contains 5 peptides corresponding to SARS-CoV spike protein sequence. The sequences have been tested for HLA binding with SARS-CoV protein and includes a positive and a negative control. CV1, CV2 and CV3 sequences are also seen within the spike glycoprotein of SARS-CoV2. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The peptide epitopes can be used in ELISPOT, cytokine and CTL assays. The sequences in the set are, CV1- VLNDILSRL CV2- NLNESLIDL CV3- FIAGLIAIV CV4- KLPDDFMGCV (+ve control) CV5- AYRPPNAPIL (-ve control)
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Size | 0.25 mg NET peptide |
References | 1. Lv Y, et al. Identification of a novel conserved HLA-A* 0201-restricted epitope from the spike protein of SARS-CoV. BMC immunology. 2009 Dec 1;10(1):61.2. Ahmed SF et al. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020 Mar;12(3):254. |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.